Costelli P, Tessitore L, Batetta B, Mulas M F, Spano O, Pani P, Baccino F M, Dessì S
Dipartimento di Medicina ed Oncologia Sperimentale, Sezione di Patologia Generale, Universitá di Torino, Italy.
J Nutr. 1999 Mar;129(3):700-6. doi: 10.1093/jn/129.3.700.
The ascites hepatoma Yoshida AH130 causes in the host a rapid and progressive body weight loss, associated with reduced food intake, and protein and lipid hypercatabolism. Because insulin regulates glucose as well as lipid and protein metabolism, we suggest that the observed alterations are at least in part secondary to hypoinsulinemia and/or to the increase of counterregulatory hormones in AH130-bearing rats. To verify this hypothesis, controls with free access to food (n = 4), controls with free access to food plus insulin (107 micromol. kg body wt-1. d-1) (n = 4), controls pair-fed to the tumor-bearing rats (n = 4), pair-fed controls treated with insulin (n= 4), tumor hosts (n = 9), and tumor hosts treated with insulin (n = 6) were used. The Yoshida ascites hepatoma cells ( approximately 10(8) cells/rat) were inoculated intraperitoneally. Daily food intake and body weight were measured; insulin was injected starting the day of tumor implantation for 6 d. The metabolism of both cholesterol and lipids was investigated in tumor cells, and ascitic fluid and blood serum were investigated at the end of treatment. Insulin prevented the reduction of food intake (19 +/- 0.6 vs. 13 +/- 0.4 g/d, P < 0.01; AH130 hosts treated and not treated with insulin, respectively), the loss of body weight (202 +/- 12 vs. 135 +/- 9 g, P < 0.01), lowered the circulating triglycerides (48.3 +/- 4.9 vs. 84.5 +/- 7.1 mmol/L, P < 0.01), and free fatty acids (561 +/- 47 vs. 989 +/- 54 mmol/L (P < 0.01), while corrected the decrease of adipose lipoprotein lipase activity (1,240 +/- vs. 300 +/- pmol FA, P < 0.01) observed in AH130 hosts. Moreover, insulin prevented the decrease in HDL cholesterol (13.2 +/- 0.8 vs. 9.3. +/- 0.7 mmol/L, P < 0.01) and significantly increased hepatic cholesterol synthesis as evaluated by 14C-acetate incorporation into cholesterol, in both liver (3,337 +/- 245 vs. 830 +/- 115 Bq/g, P < 0.01) and AH130 cells (11,676 +/- 1,693 vs. 4,196 +/- 527 Bq/10(6) cells, P < 0.01). Thus insulin treatment ameliorated many metabolic derangements, with a lengthening of rats survival time (7 +/- 1 vs. 11 +/- 1 d, P < 0.05) without significantly stimulating tumor growth. These data, together with our previous observations on the effectiveness of insulin on protein turnover perturbations, suggest that many metabolic alterations occurring during cancer cachexia can be avoided by the administration of this hormone.
吉田腹水型肝癌AH130可使宿主迅速且渐进性体重减轻,伴有食物摄入量减少以及蛋白质和脂质分解代谢亢进。由于胰岛素可调节葡萄糖以及脂质和蛋白质代谢,我们认为观察到的这些改变至少部分是由荷AH130大鼠的低胰岛素血症和/或对抗调节激素增加所致。为验证这一假设,我们选用了自由进食的对照组(n = 4)、自由进食加胰岛素(107 μmol·kg体重-1·d-1)的对照组(n = 4)、与荷瘤大鼠配对喂食的对照组(n = 4)、接受胰岛素治疗的配对喂食对照组(n = 4)、肿瘤宿主(n = 9)以及接受胰岛素治疗的肿瘤宿主(n = 6)。将吉田腹水型肝癌细胞(约108个细胞/大鼠)腹腔内接种。每日测量食物摄入量和体重;从肿瘤植入当天开始注射胰岛素,持续6天。在肿瘤细胞中研究胆固醇和脂质的代谢,并在治疗结束时对腹水和血清进行研究。胰岛素可防止食物摄入量减少(分别为19±0.6与13±0.4 g/d,P<0.01;分别为接受和未接受胰岛素治疗的AH130宿主)、体重减轻(202±12与135±9 g,P<0.01),降低循环甘油三酯水平(48.3±4.9与84.5±7.1 mmol/L,P<0.01)以及游离脂肪酸水平(561±47与989±54 mmol/L,P<0.01),同时纠正了在AH130宿主中观察到的脂肪脂蛋白脂肪酶活性降低(1240±与300±pmol FA,P<0.01)。此外,胰岛素可防止高密度脂蛋白胆固醇降低(13.2±0.8与9.3±0.7 mmol/L,P<0.01),并通过14C-乙酸掺入胆固醇来评估,显著增加肝脏(3337±245与830±115 Bq/g,P<0.01)和AH130细胞(11676±1693与4196±527 Bq/106个细胞,P<0.01)中的肝脏胆固醇合成。因此,胰岛素治疗改善了许多代谢紊乱,延长了大鼠存活时间(7±1与11±1天,P<0.05),而未显著刺激肿瘤生长。这些数据,连同我们之前关于胰岛素对蛋白质周转紊乱有效性的观察结果,表明通过给予这种激素可避免癌症恶病质期间发生的许多代谢改变。